3.49
Scinai Immunotherapeutics Ltd ADR stock is currently priced at $3.49, with a 24-hour trading volume of 1.40M.
It has seen a +23.76% increased in the last 24 hours and a +693.18% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.03 pivot point. If it approaches the $3.91 resistance level, significant changes may occur.
Previous Close:
$2.82
Open:
$2.9
24h Volume:
1.40M
Market Cap:
$2.03M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-1.1506
EPS:
-3.0332
Net Cash Flow:
$-9.42M
1W Performance:
+17.51%
1M Performance:
+693.18%
6M Performance:
+359.21%
1Y Performance:
+0.00%
Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd ADR
Sector
Industry
Phone
972 8 930 2529
Address
Jerusalem BioPark Building, 2nd floor Hadassah Ein Kerem Campus, Jerusalem
Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Latest News
Scinai receives EIB terms for loan-to-equity conversion By Investing.com - Investing.com
Investing.com
Scinai Immunotherapeutics Ltd ADR (SCNI) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
The InvestChronicle
Scinai Immunotherapeutics Ltd ADR Inc. (SCNI) Price Performance: A Technical Analysis Perspective - The InvestChronicle
The InvestChronicle
Scinai regains Nasdaq compliance, eyes EIB loan conversion By Investing.com - Investing.com
Investing.com
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ... - Investing.com UK
Investing.com UK
Quarterly Metrics: Quick and Current Ratios for Scinai Immunotherapeutics Ltd ADR (SCNI) – DWinneX - The Dwinnex
The Dwinnex
Scinai Immunotherapeutics Ltd ADR Stock (SCNI) Financials Data
Scinai Immunotherapeutics Ltd ADR (SCNI) Net Income 2024
SCNI net income (TTM) was -$9.29 million for the quarter ending September 30, 2023, a -4,990% decrease year-over-year.
Scinai Immunotherapeutics Ltd ADR (SCNI) Cash Flow 2024
SCNI recorded a free cash flow (TTM) of -$9.42 million for the quarter ending September 30, 2023, a +31.34% increase year-over-year.
Scinai Immunotherapeutics Ltd ADR (SCNI) Earnings per Share 2024
SCNI earnings per share (TTM) was -$5.20 for the quarter ending September 30, 2023, a -783.00% decline year-over-year.
About Scinai Immunotherapeutics Ltd ADR
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Cap:
|
Volume (24h):